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Abstract
Introduction: In granulomatosis with polyangiitis (GPA), a complex autoimmune small-vessel vasculitis frequently
associated with chronic necrotizing inflammation of the nasal mucosa, elevated nasal Staphylococcus (S.) aureus
carrier rates are a risk factor for relapse. As cytokines are primarily involved in the regulation of defense against
potentially pathogenic microorganisms, the aim of this study was to compare healthy individuals and GPA patients
with respect to their baseline cytokine expression of nasal epithelial cells (NEC), which form the first barrier against
such triggers. The ability of S. aureus to influence the nasal microenvironment’s cytokine secretion was assessed by
exemplary stimulation experiments.
Methods: Baseline expression of 19 cytokines of primary NEC of GPA patients and normal controls (NC) was
quantified by a multiplex cytokine assay. Stimulation experiments were performed with supernatants of S. aureus
and expression of interleukin-8 was determined by ELISA.
Results: In GPA, an altered pattern of baseline cytokine expression with significantly up-regulated G-CSF and
reduced interleukin (IL)-8 concentrations was observed. Both NEC of GPA patients and NC responded to
stimulation with S. aureus, but GPA patients displayed a significantly lower IL-8 secretion and a diminished dynamic
range of response towards the stimulus.
Conclusions: The data presented underline the hypothesis of a disturbed epithelial nasal barrier function in GPA.
The dysregulated baseline expression of G-CSF and IL-8 and the reduced response to microbial stimulation may
facilitate changes in the composition of the nasal flora and favour an imbalanced inflammatory response, which
might be relevant for the disease course.
Introduction
Granulomatosis with polyangiitis (GPA) is characterized
by chronic necrotizing granulomatous inflammation
with a predilection of the upper and lower respiratory
tract and proteinase 3 (PR3) specific cytoplasmic anti-
neutrophil cytoplasmatic antibodies (C-ANCA) [1,2].
So far, the pathogenetic mechanisms resulting in inflam-
mation and autoimmunity in GPA are poorly elucidated.
A complex interaction between genetic susceptibility and
environmental factors is discussed [3-6], whereas low
familiar clustering [7] stresses the importance of the latter.
Epidemiological studies revealed higher Staphylococcus
(S.) aureus colonisation rates in GPA-patients compared
to healthy and diseased controls [8-10]. Moreover, nasal
carriage was shown to be associated with significantly ele-
vated relapse rates, endonasal disease activity and first
manifestation in the upper respiratory tract [8,11,12]. In
addition, treatment with trimethoprim/sulfamethoxazole
reduces the annual number of respiratory infections and
the incidence of relapses in GPA-patients in remission
[10,13,14].
Various staphylococcal superantigens were demon-
strated to exert strong stimulatory effects on immunocom-
petent cells [15]. Furthermore, T-cells were shown to
exhibit irregular modes of differentiation and cytokine
expression upon stimulation with S. aureus [16,17], and
S. aureus specificity was found in T-cell clones generated
from peripheral blood lymphocytes of GPA-patients [17].
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Remarkably, recent findings suggest a dysbalanced
microbiom of the nasal cavity rather than a distinct micro-
bial trigger comparable to the dysbiosis in inflammatory
bowel diseases like Morbus Crohn [18]. Kain et al. demon-
strated that in ANCA-associated systemic vasculitides
highly prevalent auto-antibodies to lysosomal membrane
protein-2 can cross-react with adhesins of gram-negative
pathogens [19].
Another hint at microbial triggering of GPA is given by
Pendergraft et al. demonstrating that patients harbouring
PR3-ANCA also produce auto-antibodies to complemen-
tary PR3 (cPR3), a peptide translated from the antisense
DNA strand of PR3. Conversely, the presence of cPR3
leads to production of both anti-cPR3 and anti-PR3 auto-
antibodies. Genetic sequences that could be translated to
cPR3-peptides were identified in numerous microbial
and fungal organisms, including S. aureus, Entamoeba
histolytica and Ross-River virus [20].
Taken together, the evidence is increasingly pointing
to an imbalanced inflammatory response to microbial
challenge as a potentially relevant process in the patho-
genesis of GPA or vice versa.
Cytokines are significantly involved in the regulation of
immune and inflammatory processes [21]. They enable
inter-cellular communication and initiate immune
responses by recruiting and activating specific immune
cells, thus playing a decisive role in successful local defense
against microorganisms [22]. Although aberrant cytokine
patterns in GPA-patients in serum or plasma [23-25],
mononuclear cells [26,27], pulmonary lesions [28,29] and
bronchoalveolar lavage fluid [30] are verified by numerous
studies, so far no study has been performed to assess
altered cytokine expression in nasal epithelial cells, which
form the first barrier against potential exogenous triggers.
We hypothesized an alteration in the prevailing pattern
of cytokine expression of nasal epithelial cells especially
focusing on microbial defense. The main objectives of this
study were, therefore, to determine: i) the basal expression
levels of 19 cytokines closely linked to microbial defense
mechanisms on protein level in GPA-patients and normal
controls and, furthermore, ii) the ability of S. aureus to
influence the nasal microenvironment’s cytokine secretion
by exemplary stimulation experiments.
Materials and methods
Patients and biopsies
For analysing baseline cytokine secretion, nasal mucosa
biopsies were obtained from 20 patients with GPA and 19
normal controls (NC). For stimulation experiments, biop-
sies of 10 GPA-patients and 10 NC were generated. Biop-
sies were taken from nasal turbinates at sites that were
visually free of disease activity and suspect alterations like
granuloma, edema, bloody patches, purulent secretion or
crusts.
The study protocol was approved by the ethics com-
mittee of the University of Kiel, Germany (AZ A101/07)
and was in accordance with the principles of the Declara-
tion of Helsinki (latest revision October 2008). All
patients provided written informed consent prior to
enrolment. Exclusion criteria included pregnancy, hae-
mostatic disorder and age of less than 18 years.
GPA was diagnosed according to the American College
of Rheumatology classification criteria and Chapel Hill
definitions for GPA as recommended by the European Lea-
gue Against Rheumatism (EULAR) [31]. GPA-subgroups
were determined according to the European Vasculitis
Study Group definitions and recent EULAR recommenda-
tions [31]. Extent of the disease was assessed by the Disease
Extent Index (DEI) [32], disease activity was classified using
the Birmingham Vasculitis Activity Score (BVAS) [33]. The
Vasculitis Damage Index (VDI) was applied to record
organ damage as a consequence of granulomatous inflam-
mation and vasculitis [34,35]. All patients underwent a
standardized interdisciplinary evaluation [36] and were
examined endoscopically by an ear, nose and throat -
specialist to evaluate endonasal GPA activity [2].
In order to assess the presence of systemic inflamma-
tion, white blood cell counts (WBC) as well as measure-
ment of C-reactive protein (CRP) concentration and
erythrocyte sedimentation rate (ESR) were performed.
Besides slightly elevated ESR, as typical in GPA patients
[37], all serologic parameters were within the normal
range. In case of GPA, serologic titers of PR3-specific
C-ANCA and myeloperoxidase-specific P-ANCA were
determined according to Savige et al. [38].
In the normal control group, biopsies were taken while
doctors were performing airway passage improving sur-
gery. No individual of this group showed anamnestic or
endoscopic signs of acute or chronic inflammatory or
autoimmune alterations of the nasal mucosa or was
under immunomodulating medication.
Detailed description of patient groups is given in
Tables 1 and 2.
Primary cell culture
Nasal epithelial cells (NEC) were enzymatically isolated
from biopsies using dispase (Invitrogen, Karlsruhe,
Germany). The cells were grown in Airway Epithelial
Cell Growth medium (Promocell, Heidelberg, Germany)
in a 96-well plate until pre-confluence with approxi-
mately equal numbers of cells per well were obtained.
After a mean cultivation time of 13 days, supernatants
were collected and stored at -80°C.
Multiplex cytokine assay
The supernatants of NEC were analysed by performing
a Bio-Plex™ Cytokine Assay according to the manufac-
turer’s instructions (Bio-Rad Laboratories, Munich,
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Table 1 Patients’ characteristics





(n = 19) (n = 20) (n = 10) (n = 10)
Age (yrs, mean and range) 39.50 (18 to 76) 51.55 (24 to 71) 43.30 (23 to 56) 50.80 (24 to 71)
Sex 11 male, 8 female 12 male, 8 female 7 male, 3 female 7 male, 3 female
First GPA manifestation till study entry (yrs, median and
range)
3.8 (19 to 0) 3.3 (9 to 0)











WBC (cells/nl) 6.74 1.55 8.22 2.82 7.87 1.97 7.77 2.33
ESR 1st h (mm) 8.14 3.94 33.00 27.60 8.00 2.92 52.40 35.61
median range median range median range median range
CRP (mg/dl) 1.30 0.9 to
5.8








P-ANCA-titre (1:) 0 0 to 640 0 0 to 61
Table 2 Characteristics of patients with GPA
Baseline cytokine secretion Stimulation
n % n %
Biopsy proof GPA 12 60 7 70
EULAR subgroups generalized 14 70 8 80
early systemic 5 25 1 10
local 1 5 0 0
severe 0 0 1 10
EULAR disease activity remission 6 30 2 20
response 0 0 1 10
relapse, minor 8 40 2 20
relapse, major 4 20 3 30
refractory 1 5 0 0
low-activity 1 5 2 20
Endoscopy: endonasal activity none 12 60 4 40
mild 7 35 4 40
moderate 0 0 2 20
not evaluated 1 5 0 0
Disease scores median (range) median (range)
DEI 2 (0 to 5) 2 (0 to 5)
BVAS-1 3 (0 to 13) 1.5 (0 to 12)
BVAS-2 0 (0 to 4) 0 (0 to 4)
VDI 0.5 (0 to 3) 2 (0 to 4)
Immunomodulating therapy n (%) mean value (mg) n (%) mean value (mg)
prednisolone 19 (95) 12.89 9 (90) 10.67
methotrexate 10 (50) 22.25 2 (20) 20
cyclophosphamide regular 3 (15) 133.33 1 (10) 100
cyclophosphamide bolus 2 (10) 1000 2 (20) 1000
azathioprine 2 (10) 125 2 (20) 125
leflunomide 2 (10) 25 2 (20) 25
mycophenolate mofetil 1 (5) 2000 0 (0) 0
cummulative cyclophosphamide 6 (30) 45.17 (g) 8 (80) 14.88 (g)
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Germany) allowing quantification of multiple cytokines
with broad range standard curves in small-sample-sizes.
Pro-inflammatory (interleukin (IL)-1a, IL-1b, IL-5, IL-6,
IL-7, IL-8, IL-17, tumour necrosis factor-alpha (TNF-a))
and anti-inflammatory (IL-4, IL-10, IL-13) mediators,
proteins mainly associated with adaptive immune
responses (IL-2, IL-4, IL-12p70, IL-13, IFN-g) or with
recruitment of immune cells (IL-8, MCP-1, MIP-1), cyto-
kines predominantly responsible for proliferation of
inflammatory effector cells (G-CSF, GM-CSF) and con-
trol of apoptotic procedures associated with inflamma-
tion (TNF-b) were investigated.
Briefly, samples of 50 µl NEC supernatant were incu-
bated with anti-cytokine antibody-coupled beads. After
washing, the complexes were incubated with biotinylated
anti-cytokine detection antibodies, and finally with strepta-
vidin-phycoerythrin. Cytokine concentrations were mea-
sured using a Luminex 96-well plate reader (Bio-Plex™
100-Multiplex-Suspension-Array-Reader; Bio-Rad Labora-
tories, Munich, Germany) and the Bio-Plex™ Manager
Software 4.1.1 (Bio-Rad Laboratories, Munich, Germany).
Human recombinant cytokines were used as standards.
Stimulation of human nasal epithelial cells with S. aureus
For stimulation of NEC, supernatants containing the bac-
terial secretory products of S. aureus strain T190-2
(kindly provided by B.M. Bröker, University of Greifs-
wald, Germany), which has been described to predomi-
nate in nasal isolates in Western Europe, was chosen.
The S. aureus supernatants were not analysed for viru-
lence factors secreted into the growth medium. However,
in PCR analysis the test strain was positive for toxic
shock and enterotoxin genes [39]. Experiments were per-
formed corresponding to Sachse et al. [40]. According to
the results of preliminary experiments concerning time
and dose dependency (8, 12, 16, 24 hours; data not
shown), stimulation experiments were performed with
S. aureus supernatants diluted 1:5 in a final volume of
300 µl for 24 hours. An impact of the bacterial growth
medium tryptic soy broth on the stimulation was ruled
out before and NEC incubated in fresh cell culture med-
ium without bacterial supernatants served as controls.
Cell viability greater than 95% was verified by trypan blue
dye exclusion test, and vital cell morphology was con-
trolled in phase contrast microscopy. Moreover, 10 µl of
cell culture supernatants were incubated on Columbia
blood agar to prove absence of bacterial contamination.
After stimulation, cell culture supernatants were col-
lected and stored at -80°C until analysis.
Quantification of IL-8 via ELISA
IL-8 concentrations in cell culture supernatants after sti-
mulation were determined in duplicate by standard ELISA
using the BD OptEIA human IL-8 set (BD Biosciences,
San Diego, CA, USA).
Statistical analysis
All statistics were performed in an exploratory manner
using SPSS statistical software for Windows, version 18
(SPSS Inc., Chicago, IL, USA). Based on the Shapiro-Wilk-
Test, normal distribution could be assumed for neither the
entire Bio-Plex™ data nor for the delta values (stimulated -
basal) of the stimulation experiments. Therefore, differ-
ences between the two groups (GPA versus NC) were
evaluated by the nonparametric Mann-Whitney-U-Test.
Normally distributed stimulation data were analysed by
means of a general linear model for repeated measurement
procedures in order to test the effects of within-subject
factors (effect of stimulation within each group) and of
between-subject factors (comparison of GPA- and NC-
group). A P-value of ≤0.05 was regarded as statistically
significant.
Results
Altered pattern of baseline cytokine expression in GPA-
patients
For 17 of the analysed 19 cytokines in the supernatants of
NEC, no difference between GPA-patients and normal
controls could be detected (see Table 3 for details).
In contrast, NEC of GPA-patients showed significantly
higher protein expression of granulocyte colony-stimulat-
ing factor (G-CSF, P = 0.050). Furthermore, concentrations
of interleukin-8 (IL-8, CXCL8) were remarkably reduced
in NEC of GPA-patients compared to NC (P = 0.009), as
illustrated in Figure 1.
Diminished response to stimulation with S. aureus culture
supernatants in GPA-patients
Based on the results of the multiplex cytokine assay, a
more detailed functional study of IL-8 expression of NEC
upon stimulation with secretory products containing S.
aureus-culture-supernatants was performed.
While both groups (GPA and NC) showed a statistically
significant response to the stimulus (NC: P = 0.005, GPA:
P = 0.005), baseline IL-8 expression (mean value 1,247.9,
SD 881.6, maximum 2,735.3, minimum 379.0 pg/ml) as
well as IL-8 expression after stimulation (mean value
2,753.0, SD 1,938.2, maximum 6,744.4, minimum 776.5
pg/ml) was significantly lower (P = 0.006) in GPA-patients
compared to NC (basal: mean value 2,876.1, SD 1,498.3,
maximum 4,935.5, minimum 500.0 pg/ml; stimulated:
mean value 5,647.4, SD 2,407.9, maximum 9,516.1, mini-
mum 1,521.9 pg/ml), as demonstrated in Figure 2A.
Remarkably, also the dynamic range of the reaction (sti-
mulated minus basal) was considerably more restricted in
NEC of GPA-patients (P = 0.029, Figure 2B).
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No correlation between nasal S. aureus-colonisation,
endonasal GPA-activity or prednisolone dosages and
these results could be detected (data not shown).
Discussion
Cytokines’ elaborate interplay enables inter-cellular
communication and constitutes a crucial part in the
Table 3 Baseline cytokine expression of nasal epithelial cells (pg/ml)
Normal control (NC) Granulomatosis with polyangiitis (GPA) NC vs. GPA
median range median range P-value
IL- 1a 71.74 <1.51 to 319.24 92.38 7.90 to 477.11 0.322
IL-1b <2.67 <2.67 to 8.67 2.70 <2.67 to 12.74 0.224
IL-2 <1.42 <1.42 to 6.46 3.60 <1.42 to 6.00 0.070
IL-4 <0.32 <0.32 to 0.80 <0.32 <0.32 to 0.72 0.283
IL-5 below detection limit (<2.51)
IL-6 26.22 2.81 to 788.29 29.61 3.70 to 139.47 0.607
IL-7 below detection limit (<2.43)
IL-8 1388.14 <1.77 to 5188.14 319.16 <1.77 to 3708.72 0.009
IL-10 below detection limit (<1.78)
IL-12 <2.55 <2.55 to 3.75 <2.55 <2.55 to 4.03 0.283
IL-13 below detection limit (<2.68)
IL-17 2.77 <1.87 to 6.41 3.54 <1.87 to 6.01 0.101
G-CSF 19.60 <1.31 to 204.41 61.30 1.53 to 663.58 0.050
GM-CSF 10.50 <0.74 to 28.70 12.50 7.74 to 21.56 0.084
IFN-g 4.61 <1.61 to 21.41 5.92 2.27 to 18.18 0.089
MCP-1 3.66 <1.81 to 8.21 4.12 <1.81 to 7.90 0.667
MIP-1b <1.41 <1.41 to 2.37 1.43 <1.41 to 2.79 0.141
TNF-a <6.42 <6.42 to 13.46 <6.42 <6.42 to 11.00 0.296
TNF-b 9.44 <2.14 to 24.46 14.20 3.35 to 23.40 0.054
Figure 1 Baseline cytokine expression. Significantly altered baseline cytokine expression of primary nasal epithelial cells concerning G-CSF (A)
and IL-8 (B) of granulomatosis with polyangiitis (GPA) patients compared to normal controls (NC). Data are represented as box plots showing
the median as a straight line; the boxes correspond to the 75th and 25th percentiles and the whiskers indicate normal variation limits.
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regulation of immune and inflammatory processes - two
important components in the pathogenesis of GPA - thus
allowing an adequate response to microbial challenges.
Apart from Balding et al., who described an altered Th2-
cytokine milieu in nasal biopsies [41], no comprehensive
analysis of baseline cytokine expression in the nasal
epithelium of GPA-patients has been performed so far.
For GPA, alterations in cytokine levels in pulmonary
lesions have been described [28,29], but none of the 19
cytokines relevant for microbial defense included in this
study were examined. Results of Richter et al., who
reported elevated concentrations of the pro-inflammatory
cytokines IL-1a, IL-1b and IL-6 in bronchoalveolar
lavage fluid of GPA-patients [30], are difficult to compare
to our findings obtained from a distinct compartment
but hint at an altered cytokine spectrum.
Once induced by an inflammatory stimulus, almost all
tissues within the human body are capable of producing
G-CSF, thus leading to an increase in number and activa-
tion of neutrophils [42]. G-CSF serum levels are markedly
elevated in response to infection and usually fall in parallel
with the recovery process [43], whereas they remain ele-
vated and correlate with disease activity in chronic inflam-
matory conditions, such as rheumatoid arthritis and Behçet
disease [44,45]. Locally elevated G-CSF concentrations
have also been observed in inflammatory bowel disease
[46]. These findings match our results of locally elevated
concentrations in NEC reasonably.
A prolonged life time of neutrophils resulting from a
delayed apoptosis induced by G-CSF [47] increases the
possibility of being primed and expressing PR3 on the cell
surface [23,48]. Further activation through binding of
ANCA can result in damage and lysis of endothelial cells
[49]. In endothelial cells, G-CSF has been shown to down-
regulate lipopolysaccharide-induced IL-8 expression [50],
which would be conceivable for epithelial cells as well.
Besides, the possible ability of G-CSF to reduce neutrophil
killing of S. aureus [51] could have tremendous negative
impacts on an effective immune defense.
IL-8 chemoattracts polymorphonuclear neutrophils
(PMN) and monocytes and further promotes their activa-
tion [52], thus creating and maintaining an inflammatory
microenvironment at the site of infection.
Lamprecht et al. suggested a down-regulation of mono-
cytic production of IL-8 during the course of GPA [26],
which is in line with our findings. Stimulation of PMN
with IL-8, especially after previous treatment with TNF-
a, leads to PR3 translocation to the cell surface [53], thus
providing the prerequisite for interactions with PR3-
ANCA, which directly activates diverse inflammatory
Figure 2 Effect of stimulation with S. aureus. Significant differences in IL-8 expression of primary nasal epithelial cells (NEC) comparing
granulomatosis with polyangiitis (GPA) patients and normal controls (NC) before and after stimulation with S. aureus supernatants (A, P = 0.006).
Furthermore, the dynamic range (Δ IL-8, secretion after stimulation minus basal secretion) is significantly reduced in GPA-patients (B, P = 0.029).
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reactions in PMN [54]. Variation of IL-8 expression levels
is fine-tuned by graduated activation of at least three sig-
naling pathways: NF-B, JNK (JUN-N terminal protein
kinase) and p38-MPK (mitogen-activated protein kinase)
[55]. In order to evaluate whether this complex interplay is
operating effectively in GPA-patients, we stimulated NEC
with culture supernatants of S. aureus, which apart from
its particular role in the pathogenesis of GPA has been
shown to be a potent inducer of IL-8 expression in nasal
epithelial cells [56,57]. The imbalance of IL-8 with a
reduced baseline expression and a diminished response to
bacterial stimulus of GPA-NEC could reasonably lead to a
shift in the microbial flora towards an overbalance of
facultative pathogenic microorganisms.
These data, in addition to the observation of a severely
impaired ciliar beat frequency [58] and a reduced pro-
duction of the antimicrobial peptide human b-defensin 3
of NEC upon stimulation with S. aureus [59], as well as
an imbalanced regulation of genes involved in epithelial
barrier function [18], fortify the hypothesis of considering
GPA a disease with a disturbed epithelial barrier function
as was also discussed for other chronic inflammatory dis-
eases with nasal involvement [60].
However, this study has its limitations. Patients with
GPA received immunomodulating therapy, for which
negative impact on cytokine expression has been described
[61,62]. Differential expression of the investigated cyto-
kines (most of them without differences between NC and
GPA) argues for successful prevention of such effects by
cultivating NEC for an average of 13 days prior to the
investigation.
The fact that the pattern of cytokine expression of NEC
can be influenced by external stimuli paves the way for
local pharmacological interference. Shifting the basal
cytokine balance towards a higher IL-8 level, for example,
by applying recombinant human IL-8 [63] or non-patho-
genic bacteria components [64] could be a future thera-
peutic option.
Conclusions
Taken together, our data suggest a specifically altered pat-
tern of baseline cytokine expression of the nasal epithe-
lium in patients with GPA compared to NC. This can
facilitate changes in the composition of microbial colonisa-
tion and favour an imbalanced inflammatory response to
microbial challenge and thus disease exacerbation. Our
findings of an aberrant response to S. aureus stimulation
in patients with GPA further underline this hypothesis. It
remains to be investigated whether our results exemplify a
general alteration in the reactive cytokine response to
external stimuli. Taken into account the results of all 19
examined cytokines, we assume pathophysiological rele-
vance of IL-8 and G-CSF in GPA, which could have
potential therapeutic implications.
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